Acoramidis

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications

ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with experts.

ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with experts.

Journal: Therapeutic advances in cardiovascular disease
Published: April 02, 2026

Early Five-Month Response to Acoramidis in ATTR-CM Assessed by SUVmax Using 99mTc-HMDP SPECT/CT.

Early Five-Month Response to Acoramidis in ATTR-CM Assessed by SUVmax Using 99mTc-HMDP SPECT/CT.

Journal: QJM : monthly journal of the Association of Physicians
Published: March 31, 2026

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.

Journal: JAMA cardiology
Published: March 30, 2026

Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM.

Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM.

Journal: Future cardiology
Published: February 09, 2026

2025 New Drug Update (Part 2): Recent Approvals and Clinical Implications.

2025 New Drug Update (Part 2): Recent Approvals and Clinical Implications.

Journal: The Senior care pharmacist
Published: January 20, 2026

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

Journal: Current problems in cardiology
Published: January 07, 2026

Hidden overlap between heart failure with preserved ejection fraction and transthyretin amyloid cardiomyopathy: Why it matters and how to avoid missing it.

Hidden overlap between heart failure with preserved ejection fraction and transthyretin amyloid cardiomyopathy: Why it matters and how to avoid missing it.

Journal: International journal of cardiology
Published: December 22, 2025

Attruby for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Attruby for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Journal: Trends in pharmacological sciences
Published: December 17, 2025

Acoramidis (Beyonttra®) : a new era in the treatment of transthyretin amyloid cardiomyopathy

Acoramidis (Beyonttra®) : a new era in the treatment of transthyretin amyloid cardiomyopathy

Journal: Revue medicale de Liege
Published: December 15, 2025

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.

Journal: Future cardiology
Published: December 12, 2025

Pyrazole-Based Transthyretin Kinetic Stabilizers Identified Using a Covalent Fluorescent Probe Assay for Selectivity Profiling in Human Serum.

Pyrazole-Based Transthyretin Kinetic Stabilizers Identified Using a Covalent Fluorescent Probe Assay for Selectivity Profiling in Human Serum.

Journal: Journal of medicinal chemistry
Published: December 09, 2025

Identification of Acoramidis as a Repurposed Inhibitor of the DNA Sanitization Enzyme MutT Homologue 1.

Identification of Acoramidis as a Repurposed Inhibitor of the DNA Sanitization Enzyme MutT Homologue 1.

Journal: ACS pharmacology & translational science
Published: December 03, 2025
Showing 1-12 of 79

Last Updated: 04/28/2026